Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to evaluate the efficacy and safety of GW05 administered in 3 regimens versus metronidazole 0.75% for the treatment of bacterial vaginosis.
| Condition | Intervention | Phase |
|---|---|---|
|
Vaginosis, Bacterial Vaginal Infection |
Drug: GW05 Drug: Metronidazole |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | A Multicenter, Randomized, Investigator-Blinded, Phase 2, Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis |
- proportion of subjects with therapeutic cure [ Time Frame: day 21 to day 30 ] [ Designated as safety issue: No ]
| Enrollment: | 255 |
| Study Start Date: | January 2010 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1D |
Drug: GW05
vaginal gel once daily regimen A
|
| Active Comparator: 3D |
Drug: GW05
vaginal gel once daily regimen B
|
| Active Comparator: 5D |
Drug: GW05
vaginal gel once daily regimen C
|
| Active Comparator: Metronidazole |
Drug: Metronidazole
vaginal gel 0.75% once daily for 5 days
|
Detailed Description:
This is a multicenter, randomized, investigator-blinded, phase 2, dose ranging study of GW05 vaginal gel administered in 3 regimens compared to metronidazole 0.75% (QD x 5 days) for the treatment of bacterial vaginosis. Subjects will be evaluated at three timepoints (1 screening/baseline visit, post-treatment phone call and 1 test-of-cure visit). The total study duration may be up to 30 days for a subject.
Study medication will be applied intravaginally once daily at bedtime according to the assigned dosing schedule using the supplied 5-gram vaginal applicators.
Investigator blinding will be ensured by utilizing an independent drug dispensing coordinator at each site.
Bacterial vaginosis (BV) is an infection of the vagina (birth canal) that is the result of an overgrowth of bacteria that are often normally found in the vagina. This type of vaginal infection typically does not cause irritation. The most common complaint of patients who suffer from BV is a fishy-smelling vaginal discharge. The amount of vaginal discharge may or may not be increased above a normal discharge. The bad odor may get worse after sexual intercourse or during the menstrual period. BV is also strongly associated with problems during pregnancy, such as premature (early) birth, and with an increased risk of sexually transmitted diseases. Therefore, it is important to treat the infection.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Females at least 18 years of age
- In good general health
- Confirmed current diagnosis of bacterial vaginosis (determined at study screening)
- Negative pregnancy test (for women who are able to become pregnant)
- Must abstain from sexual intercourse throughout the first 7 days of thes study
- Must abstain from alcohol ingestion during the treatment period and for one day afterward
- Must not use intra-vaginal products for the duration of the study
Exclusion Criteria:
- Pregnant, lactating, or planning to become pregnant during the study period
- Menstruating at the time of the diagnosis or anticipate the onset of menses during the treatment phase of the study
- Had a medical event within 90 days of the visit (e.g., stroke, heart attack, etc.)
- Received specific treatments/medications /therapy within the designated time period prior to study enrollment
Contacts and Locations| United States, Arizona | |
| Precision Trials | |
| Phoenix, Arizona, United States, 85032 | |
| Women's Health Research | |
| Phoenix, Arizona, United States, 85015 | |
| United States, Arkansas | |
| NEA Women's Clinic | |
| Jonesboro, Arkansas, United States, 72401 | |
| United States, California | |
| Women's Health Center Inc | |
| San Diego, California, United States, 92123 | |
| United States, Colorado | |
| Downtown Women's Healthcare | |
| Denver, Colorado, United States, 80218 | |
| United States, Florida | |
| Miami Research Associates | |
| Miami, Florida, United States, 33143 | |
| Segal Institiute for Clinical Research | |
| North Miami, Florida, United States, 33161 | |
| All Women's Healthcare of West Broward | |
| Plantation, Florida, United States, 33324 | |
| United States, Georgia | |
| Atlanta North Gynecology | |
| Roswell, Georgia, United States, 30075 | |
| United States, Illinois | |
| Women's Health Practice | |
| Champaign, Illinois, United States, 61820 | |
| United States, Massachusetts | |
| ActivMed Practices & Research | |
| Haverhill, Massachusetts, United States, 01830 | |
| United States, Michigan | |
| Grand Rapids Women's Health | |
| Grand Rapids, Michigan, United States, 49503 | |
| Saginaw Valley Medical Research Group | |
| Saginaw, Michigan, United States, 48604 | |
| United States, New Jersey | |
| Women's Health Research Center | |
| Plainsboro, New Jersey, United States, 08536 | |
| United States, Pennsylvania | |
| Drexel University College of Medicine | |
| Philadelphia, Pennsylvania, United States, 19102 | |
| United States, Tennessee | |
| Jackson Clinic | |
| Jackson, Tennessee, United States, 38305 | |
| Adams Patterson OBGYN | |
| Memphis, Tennessee, United States, 38120 | |
| United States, Texas | |
| Women's Partners in Health | |
| Austin, Texas, United States, 78705 | |
| TMC Life Research | |
| Houston, Texas, United States, 77054 | |
| United States, Virginia | |
| Tidewater Physicians for Women | |
| Norfolk, Virginia, United States, 23502 | |
| Study Director: | Sharon F Levy, MD | Graceway Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Sharon F. Levy, MD / Vice President Product Develpoment, Graceway Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01055106 History of Changes |
| Other Study ID Numbers: | GW05-0904 |
| Study First Received: | January 21, 2010 |
| Last Updated: | June 28, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Graceway Pharmaceuticals, LLC:
|
bacterial vaginosis vaginal infection vaginal discharge vaginal disease |
Additional relevant MeSH terms:
|
Vaginosis, Bacterial Bacterial Infections Vaginitis Vaginal Diseases Genital Diseases, Female Metronidazole Radiation-Sensitizing Agents |
Physiological Effects of Drugs Pharmacologic Actions Anti-Infective Agents Therapeutic Uses Antiprotozoal Agents Antiparasitic Agents |
ClinicalTrials.gov processed this record on May 19, 2013